化工社
首页MCP工作台Skills
首页工作台通知我的
llms.txt · MCP 指南隐私政策 · 服务条款 · 支持v1.8.3
  1. 首页
  2. /化合物

枸橼酸他莫昔芬

Tamoxifen Citrate

HCID 2733525
新建反应
打印
基本信息概述名称与标识性质安全与法规化学与工业相关反应化合物笔记
子结构检索查找相似结构

基本信息

CAS
54965-24-1
标准SMILES
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChIKey
FQZYTYWMLGAPFJ-OQKDUQJOSA-N
分子式
C32H37NO8
平均分子量
563.6 g/mol
单同位素质量
563.25191714

概述

Tamoxifen Citrate can cause developmental toxicity according to state or federal government labeling requirements.

名称与标识

首选名称
Tamoxifen Citrate
IUPAC
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
中文名
枸橼酸他莫昔芬
英文名
Tamoxifen citrate
分子式
C32H37NO8
分子量
563.64

名称与别名

Tamoxifen citrate54965-24-1ZitazoniumKessarZemideJenoxifenLedertamNourytamTamofeneNoxitemOncotamTamofen
展开更多名称
他莫他莫西芬枸橼酸他昔芬苯氧胺枸橼酸枸缘酸他莫昔芬枸橼酸他莫昔芬枸橼酸三苯氧胺柠檬酸他莫西芬枸橼酸他莫西芬柠檬酸三苯氧胺NOLVADEXtamoxifeneTMXSoltaMoxNolvadex(Tamoxifen)Tamoxifen Citrate TabletsTamoxifen Z-isomer citrate(Z)-[2-[4-(1,2-diphenylbut-1-enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-hydroxypropane-1,2,3-tricarboxylateTMX1TXNDC
TomaxastaZynoplexEmblonNolgenNoltamTamaxICI 46,474DTXSID8021301

数据库标识

CAS
54965-24-1
PubChem CID
2733525

性质

结构计算性质

极性表面积
145 Ų
氢键供体
4
氢键受体
9
可旋转键
13
重原子
41
形式电荷
0
复杂度
690

实验与物化性质

Human Drugs · 2 条

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Endocrine DisruptorsPotential endocrine disrupting compound
Collision Cross Section197.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学性质

熔点
140 · 140-144 °C
储存条件
2 · 2-8°C
溶解度
50 mg/mL, · methanol: soluble50mg/mL, clear, colorless
形态
Powder
颜色
White to off-white
生物来源
rabbit
水溶解性
slightly soluble
敏感性
Light Sensitive & Hygroscopic
Merck
14 · 14,9048
BCS Class
1 · 1
稳定性
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
主要应用
pharmaceutical (small molecule)

安全与法规

安全信息仅供参考,不能替代供应商安全技术说明书(SDS)、适用法规与专业评估。

GHS分类

GHS Classification · 4 条

Danger

H302 (97.4%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P263, P264, P270, P273, P280, P301+P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 78 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危害信息

Regulatory Information · 2 条

Hazard Traits - Developmental Toxicity

Tamoxifen citrate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (97.4%)

毒理信息

Drug Induced Liver Injury · 6 条

Drug Induced Liver Injury Rank (DILIrank 2.0)

Tamoxifen citrate

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

安全数据

wgk
3
毒性
LD50 in mice, rats (mg/kg): 200, 600 i.p.; 62.5, 62.5 i.v.; 3000-6000, 1200-2500 orally (Furr, Jordan)
RTECS号
KH2387000
危险等级
IRRITANT

化学与工业

药理信息

FDA Pharmacological Classification · 2 条

TAMOXIFEN CITRATE

Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]

MeSH Pharmacological Classification · 4 条

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

应用领域

概述枸橼酸他莫昔芬 (三苯氧胺,tamoxifen citrat e,简称 TCT ),是一种雌激素(estrogen)竞争性拮抗剂,为非固醇类抗雌激素药物,在体内能与雌激素(雌二醇) 竞争,与乳癌细胞雌激素受体相 结合,从而抑制雌激素对癌细胞的作用,使肿瘤细胞生长发育受阻,而发挥抗癌效果。临床上常用于治疗各类乳腺癌,尤其适用于雌激素受体和孕酮受体阳性以及前列腺特异性抗原水平较低的绝经后乳腺癌妇女患者。

用途途用于治疗晚期、复发性乳腺癌和卵巢癌等病症

上下游产品信息

上游原料

三氯化铝4-溴苯酚

相关反应

2 条
新建反应记录
HRID 348778 反应方程式
HRID 348778作为反应物
HRID 553327 反应方程式
HRID 553327作为反应物

化合物笔记

本页导航基本信息概述名称与标识性质安全与法规化学与工业相关反应化合物笔记
DTXSID
DTXSID8021301
ChEMBL
CHEMBL786
UNII
7FRV7310N6
EC Number
259-415-2
InChIKey
FQZYTYWMLGAPFJ-OQKDUQJOSA-N
SMILES
C(/C1=CC=CC=C1)(\C1C=CC(OCCN(C)C)=CC=1)=C(/CC)\C1=CC=CC=C1.C(O)(C(=O)O)(CC(=O)O)CC(=O)O
CAS 数据库
54965 · 54965-24-1(CAS DataBase Reference)
EPA化学物质信息
Tamoxifen citrate (54965-24-1)
存储类别
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
安全说明
53-36/37/39-45-36-26
海关编码
29225090
危险品标志
T,Xi
危险性类别
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1Carc. 1BRepr. 1B
危险类别码
45-60-61-22-64-36/37/38
危险品运输编号
UN 3077 9 / PGIII
溴乙烷
苯乙酸
镁
溴苯
他莫昔芬
)-1,2-二苯基-1-[4-[2-(二甲基氨基)乙氧基]苯基]丁烷-1-醇
枸橼酸他莫昔芬